FDA says 4U Health sells an unapproved HIV dried blood spot self-collection kit, making it adulterated and misbranded.
What happened
FDA reviewed 4U Health’s website in March 2026 and the firm’s April 30, 2025 response to an earlier FDA letter. FDA found the company offers an HIV serological diagnostic dried blood spot card self-collection kit to individuals for at-home sample collection and shipment to labs. FDA says the kit lacks approved premarket approval or an investigational device exemption and has not been cleared through 510(k) notification.
What FDA found
The HIV DBS self-collection kit is a device offered without an approved premarket approval application or an approved investigational device exemption.
FD&C Act section 501(f)(1)(B), 21 U.S.C. 351(f)(1)(B); section 515(a), 21 U.S.C. 360e(a); section 520(g), 21 U.S.C. 360j(g)The kit is misbranded because the firm did not provide FDA notification of intent to introduce it into commercial distribution as required by section 510(k).
FD&C Act section 502(o), 21 U.S.C. 352(o); section 510(k), 21 U.S.C. 360(k)
What FDA wants
FDA asks 4U Health to immediately stop activities that adulterate or misbrand the kit and, within 15 working days of receipt, to send a written response describing corrective steps and how it will prevent recurrence.
Who should pay attention
- companies selling at-home diagnostic collection kits
- labs and telehealth services that order or process self-collected samples
- distributors of specimen collection devices
This is a summary. Read the original letter on fda.gov.